636 related articles for article (PubMed ID: 33461517)
21. Posttherapeutic skeletal muscle mass recovery predicts favorable prognosis in patients with advanced urothelial carcinoma receiving first-line platinum-based chemotherapy.
Fukushima H; Kataoka M; Nakanishi Y; Sakamoto K; Takemura K; Suzuki H; Ito M; Tobisu KI; Fujii Y; Koga F
Urol Oncol; 2018 Apr; 36(4):156.e9-156.e16. PubMed ID: 29051030
[TBL] [Abstract][Full Text] [Related]
22. The impact of skeletal muscle abnormalities on tolerance to adjuvant chemotherapy and radiation and outcome in patients with endometrial cancer.
Ganju RG; TenNapel M; Spoozak L; Chen AM; Hoover A
J Med Imaging Radiat Oncol; 2020 Feb; 64(1):104-112. PubMed ID: 31397078
[TBL] [Abstract][Full Text] [Related]
23. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
24. Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma.
Ma LX; Taylor K; Espin-Garcia O; Anconina R; Suzuki C; Allen MJ; Honorio M; Bach Y; Allison F; Chen EX; Brar S; Swallow CJ; Yeung J; Darling GE; Wong R; Kalimuthu SN; Jang RW; Veit-Haibach P; Elimova E
Cancer Med; 2021 Jan; 10(1):199-207. PubMed ID: 33295697
[TBL] [Abstract][Full Text] [Related]
25. Low skeletal muscle density is associated with poor survival in patients who receive chemotherapy for metastatic gastric cancer.
Hayashi N; Ando Y; Gyawali B; Shimokata T; Maeda O; Fukaya M; Goto H; Nagino M; Kodera Y
Oncol Rep; 2016 Mar; 35(3):1727-31. PubMed ID: 26648321
[TBL] [Abstract][Full Text] [Related]
26. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
27. Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer.
Griffin OM; Duggan SN; Ryan R; McDermott R; Geoghegan J; Conlon KC
Pancreatology; 2019 Sep; 19(6):850-857. PubMed ID: 31362865
[TBL] [Abstract][Full Text] [Related]
28. Predicting the Overall Survival in Patients with Advanced Pancreatic Cancer by Calculating L3 Skeletal Muscle Index Derived from CT.
Özkul B; Özkul Ö; Bilir C
Curr Med Imaging; 2022; 18(10):1079-1085. PubMed ID: 35240961
[TBL] [Abstract][Full Text] [Related]
29. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.
Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of CT-determined sarcopenia in patients with advanced gastric cancer.
Lee JS; Kim YS; Kim EY; Jin W
PLoS One; 2018; 13(8):e0202700. PubMed ID: 30125312
[TBL] [Abstract][Full Text] [Related]
31. A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.
Fuchs CS; Azevedo S; Okusaka T; Van Laethem JL; Lipton LR; Riess H; Szczylik C; Moore MJ; Peeters M; Bodoky G; Ikeda M; Melichar B; Nemecek R; Ohkawa S; Świeboda-Sadlej A; Tjulandin SA; Van Cutsem E; Loberg R; Haddad V; Gansert JL; Bach BA; Carrato A
Ann Oncol; 2015 May; 26(5):921-927. PubMed ID: 25609246
[TBL] [Abstract][Full Text] [Related]
32. Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy.
Rier HN; Jager A; Sleijfer S; van Rosmalen J; Kock MCJM; Levin MD
Breast; 2017 Feb; 31():9-15. PubMed ID: 27810702
[TBL] [Abstract][Full Text] [Related]
33. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy.
Rom H; Tamir S; Van Vugt JLA; Berger Y; Perl G; Morgenstern S; Tovar A; Brenner B; Benchimol D; Kashtan H; Sadot E
Ann Surg Oncol; 2022 Mar; 29(3):1553-1563. PubMed ID: 34716836
[TBL] [Abstract][Full Text] [Related]
34. Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy.
Sahin TK; Ozbay Y; Altunbulak AY; Altunbulak HI; Onur MR; Ceylan F; Guven DC; Yalcin S; Dizdar O
Int J Clin Oncol; 2024 Jun; 29(6):822-831. PubMed ID: 38565751
[TBL] [Abstract][Full Text] [Related]
35. Skeletal Muscle Loss Is an Imaging Biomarker of Outcome after Definitive Chemoradiotherapy for Locally Advanced Cervical Cancer.
Lee J; Chang CL; Lin JB; Wu MH; Sun FJ; Jan YT; Hsu SM; Chen YJ
Clin Cancer Res; 2018 Oct; 24(20):5028-5036. PubMed ID: 29959140
[No Abstract] [Full Text] [Related]
36. Prognostic Value of Third Cervical Vertebra Skeletal Muscle Index in Oral Cavity Cancer: A Retrospective Study.
Chang SW; Hsu CM; Tsai YH; Chang GH; Tsai MS; Huang EI; Tsai YT
Laryngoscope; 2021 Jul; 131(7):E2257-E2265. PubMed ID: 33433021
[TBL] [Abstract][Full Text] [Related]
37. Impact of low skeletal muscle mass and quality on clinical outcomes in patients with head and neck cancer undergoing (chemo)radiation.
Bardoscia L; Besutti G; Pellegrini M; Pagano M; Bonelli C; Bonelli E; Braglia L; Cozzi S; Roncali M; Iotti C; Pinto C; Pattacini P; Ciammella P
Front Nutr; 2022; 9():994499. PubMed ID: 36466387
[TBL] [Abstract][Full Text] [Related]
38. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
39. Low L3 skeletal muscle index associated with the clinicopathological characteristics and prognosis of ovarian cancer: a meta-analysis.
Jin Y; Ma X; Yang Z; Zhang N
J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):697-705. PubMed ID: 36720459
[TBL] [Abstract][Full Text] [Related]
40. Deep learning-based assessment of CT markers of sarcopenia and myosteatosis for outcome assessment in patients with advanced pancreatic cancer after high-intensity focused ultrasound treatment.
Nowak S; Kloth C; Theis M; Marinova M; Attenberger UI; Sprinkart AM; Luetkens JA
Eur Radiol; 2024 Jan; 34(1):279-286. PubMed ID: 37572195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
